Citations

Clear

626 citation(s) found for "Mehta, SH".

Inpatient Management of Idiopathic Parkinson’s Disease: A Retrospective Analysis (P7-15.004)
Mangipudi, Kartik, Knox, Molly, Mehta, Shyamal H.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206572 Get It

Conjugal Synucleinopathies: A Clinicopathologic Study (P7-3.014)
Halverson, Matthew , Chiu, Shannon , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Adler, Charles H. , Zhang, Nan , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204916 Get It

Neuropathological Profile of Cases with Mild Cognitive Impairment (S1.009)
Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G. , Ho, Andrew Fu Wah , Choudhury, Parichita , Adler, Charles H. , Shprecher, David , Serrano, Geidy E. , Atri, Alireza , Tremblay, Cécilia

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204810 Get It

DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Rahman, Rifaquat , Haas‐Kogan, Daphne A. , D’Andrea, Alan D. , Tanner, Kirk, Agar, Nathalie Y.R. , Wen, Patrick Y. , Wen, Patrick Yung , Agar, Nathalie Y R , D'Andrea, Alan , Shi, Diana D. , Reitman, Zachary J. , Hamerlik, Petra , Groot, John de , Sulman, Erik P. , Sarkaria, Jann N. , Tinkle, Christopher L , Bindra, Ranjit S. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | April 3, 2024 | Volume: 26 | Issue: 8 | Pages: 1367-1387

10.1093/neuonc/noae072 | PMID 38770568 Get It

Abstract DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi
Tapper, Elliot B. , Shah, Rajesh P. , Emamaullee, Juliet , Poston, Jacqueline N. , Soto, Robin J., Pillai, Anjana , Reyner, Karina, Mehta, Shivang , Ghabril, Marwan , Morgan, Timothy R. , Caldwell, Stephen H. , Ghabril, Marwan S , Warner, Matthew A. , Dunbar, Nancy M. , Sholzberg, Michelle , Sarwar, Ammar

Mayo Clinic

Hepatology | April 1, 2024 | Volume: 80 | Issue: 2 | Pages: 488-499

10.1097/hep.0000000000000856 | PMID 38557474 Get It

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Brahmania, Mayur , Kuo, Alexander , Tapper, Elliot B. , Völk, Michael , Vittorio, Jennifer , Ghabril, Marwan , Morgan, Timothy R. , Kanwal, Fasiha , Parikh, Neehar D. , Mehta, Shivang , Goldberg, David S. , Duarte‐Rojo, Andrés , Paredes, Angelo H. , Sahota, Amandeep , McElroy, Lisa M. , Thomas, Charlie, Aslam, Saima , Ramakrishnan, Sudha , Flynn, Mary M. , Volk, Michael L , Vittorio, Jennifer M , Mehta, Shivang , Winder, Scott , Im, Gene , Goldberg, David , Lai, Jennifer , Duarte-Rojo, Andres , Paredes, Angelo H , Patel, Arpan , Sahota, Amandeep , McElroy, Lisa M , Wall, Anji E , Malinis, Maricar , Aslam, Saima , Simonetto, Douglas A , Ufere, Nneka N , Ramakrishnan, Sudha , Ibrahim, Yasmin , Asrani, Sumeet K , Serper, Marina , Ghabril, Marwan S , Parikh, Neehar D , Kanwal, Fasiha , Martin, Paul B. , Winder, Gerald Scott , Lai, Jennifer C. , Patel, Arpan , Wall, Anji , Simonetto, Douglas A. , Asrani, Sumeet K. , Serper, Marina

Mayo Clinic

Hepatology | March 27, 2024 | Volume: 80 | Issue: 3 | Pages: 742-753

10.1097/hep.0000000000000870 | PMID 38536021 Get It

The liver transplantation (LT) evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures along the continuum of pre-LT care to reduce care variation and guide patient-centered care. Following a systematic literature review, candidate pre-LT measures were grouped into 4 phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance. A modified Delphi panel with content expertise in hepatology, transplant surgery, psychiatry, transplant infectious disease, palliative care, and social work selected the final set. Candidate patient-reported experience measures spanned domains of cognitive health, emotional health, social well-being, and understanding the LT process. Of the 71 candidate measures, 41 were selected: 9 for referral; 20 for evaluation and waitlisting; 7 for waitlist management; and 5 for organ acceptance. A total of 14 were related to structure, 17 were process measures, and 10 were outcome measures that focused on elements not typically measured in routine care. Among the patient-reported experience measures, candidates of LT rated items from understanding the LT process domain as the most important. The proposed pre-LT measures provide a framework for quality improvement and care standardization among candidates of LT. Select measures apply to various stakeholders such as referring practitioners in the community and LT centers. Clinically meaningful measures that are distinct from those used for regulatory transplant reporting may facilitate local quality improvement initiatives to improve access and quality of care.
Humanin variant P3S is associated with longevity in APOE4 carriers and resists APOE4‐induced brain pathology
Miller, Brendan , Kim, Su‐Jeong , Mehta, Hemal H. , Thumaty, Neehar , Kumagai, Hiroshi , Iida, Tomomitsu, McGill, Cassandra , Nurmakova, Kamila , Sullivan, Patrick M. , Ertekin‐Taner, Nilüfer , Barzilai, Nir , Cohen, Pinchas , Ertekin-Taner, Nilüfer , Cohen, Pinchas , Cao, Kevin, Pike, Christian J. , Levine, Zachary A. , Yen, Kelvin , Atzmon, Gil

Mayo Clinic

Aging Cell | March 23, 2024 | Volume: 23 | Issue: 7 | Pages: No page available

10.1111/acel.14153 | PMID 38520065 Get It

AbstractThe APOE4 allele is recognized as a significant genetic risk factor to Alzheimer's disease (AD) and influences longevity. Nonetheless, some APOE4 carriers exhibit resistance to AD even in advanced age. Humanin, a mitochondrial‐derived peptide comprising 24 amino acids, has variants linked to cognitive resilience and longevity. Our research uncovered a unique humanin variant, P3S, specifically enriched in centenarians with the APOE4 allele. Through in silico analyses and subsequent experimental validation, we demonstrated a strong affinity between humanin P3S and APOE4. Utilizing an APOE4‐centric mouse model of amyloidosis (APP/PS1/APOE4), we observed that humanin P3S significantly attenuated brain amyloid‐beta accumulation compared to the wild‐type humanin. Transcriptomic assessments of mice treated with humanin P3S highlighted its potential mechanism involving the enhancement of amyloid beta phagocytosis. Additionally, in vitro studies corroborated humanin P3S's efficacy in promoting amyloid‐beta clearance. Notably, in the temporal cortex of APOE4 carriers, humanin expression is correlated with genes associated with phagocytosis. Our findings suggest a role of the rare humanin variant P3S, especially prevalent among individuals of Ashkenazi descent, in mitigating amyloid beta pathology and facilitating phagocytosis in APOE4‐linked amyloidosis, underscoring its significance in longevity and cognitive health among APOE4 carriers.
Abstract 5444: EGFR missense mutation(s) induce OLIG2 expression to regulate glioma stem cells maintenance and therapeutic resistance
Weaver, Sidney , Miller, Aunay , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Sereduk, Chris , Kloss, Jean , Loftus, Joseph C. , Mehta, Shwetal , Tran, Nhan L. , Tran, Nhan L

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5444-5444

10.1158/1538-7445.am2024-5444 Get It

Abstract Glioblastoma (GBM) tumors contain a subpopulation of glioma stem cells (GSC) which can escape therapeutic effects through self-renewal and invasion. Epidermal growth factor receptor (EGFR) mutations are the most common alteration in GBM (50%). One example includes extracellular domain missense mutations like G598V, A289V, and R108K (10-15%). These extracellular domain missense mutations increase ligand binding affinity, inducing a highly active receptor. Earlier reports have shown these EGFR missense mutations exhibit therapeutic resistance; however, the molecular mechanism of these missense mutations in GBM remains unknown. In this study, we show high oligodendrocyte transcription factor 2 (OLIG2) expression in GSCs with EGFR-G598V and EGFR-A289V missense mutations. OLIG2 is universally expressed in glioma and essential for reprogramming GBM cells into stem-like tumor cells. Here, we report GSCs with these point mutations display increased self-renewal, growth, invasion, and therapeutic resistance. In addition, EGFR-G598V and EGFR-A289V trigger distinct downstream signaling pathways in GSCs to regulate OLIG2 function. These missense mutation(s) also represent different pathway-based GBM subclassifications, where A289V induces a Neuronal subtype and G598V induces a Glycolytic/Plurimetabolic subtype. We hypothesize that GBM tumors harboring EGFR missense mutations (G598V, A289V) influence stem cell properties via multiple pathways to evade therapeutic effects and inhibiting these different signaling pathways will decrease therapeutic resistance in GBM. Understanding the mechanism of these EGFR mutations may lead to improved therapeutic strategies for GBM patients. Citation Format: Sidney Weaver, Aunay Miller, Mylan Blomquist, James McNamara, Keely Orndorff, Chris Sereduk, Jean Kloss, Joseph Loftus, Shwetal Mehta, Nhan L. Tran. EGFR missense mutation(s) induce OLIG2 expression to regulate glioma stem cells maintenance and therapeutic resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5444.
Abstract 256: A novel transcriptional complex of OLIG2-STAT5 mediates glioma stem cell self renewal and invasion
Miller, Aunay , Cascio, Costanza Lo , Blomquist, Mylan, McNamara, James, Orndorff, Keely, Dufault, Matthew , Sereduk, Christopher, Loftus, Joseph C. , Mehta, Shwetal , Tran, Nhan L. , Tran, Nhan L , Orndorff, Keely, Sereduk, Chris

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 256-256

10.1158/1538-7445.am2024-256 Get It

Abstract Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, despite current treatment options. One of the major contributing factors to this dismal outcome is a subset of cells called glioma stem cells (GSCs) that are highly tumorigenic, invasive, and resistant to conventional treatments. Thus, studies that focus on the properties of GSC biology are needed to develop novel therapies to improve overall survival. Here we report a novel role of STAT5 in GSC stemness and survival. In GBM tumors, STAT5 has been shown to be active in the infiltrative, residual population of cells remaining post-surgery. Knockdown of STAT5 results in the decrease in GSC stemness and therapeutic resistance. Interestingly, we find that expression of OLIG2, a key cell fate factor important for the tumorigenic potential of GSCs, affects STAT5 activation with a positive correlation between OLIG2 and STAT5 mRNA expression in GBM tumors. Furthermore, we find that in GSCs expressing EGFRvIII, STAT5 interacts with OLIG2 and pharmacological inhibition of STAT5 activation or knockdown of STAT5 expression results in decrease of OLIG2-mediated GSC invasion. Together, these data suggest a novel transcriptional complex, STAT5-OLIG2, in the potential role for GSC survival, maintenance, and invasion. Citation Format: Aunay Miller, Costanza Lo Cascio, Mylan Blomquist, James B. McNamara, Keely Orndorff, Matthew Dufault, Christopher Sereduk, Joseph Loftus, Shwetal Mehta, Nhan L. Tran. A novel transcriptional complex of OLIG2-STAT5 mediates glioma stem cell self renewal and invasion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 256.